Metabolic & Bariatric Surgery

Vol. 2, Issue 7 | August 25, 2026 | Closing the gaps in knowledge...

Editor note: This issue reflects the weekly Editorial Board ballot. Ballots were counted from Colleen Kennedy; Dr. Jerry Dang, MD PhD; Phil Schauer; Samer Mattar; Shanu Kothari, MD FACS; and Teresa LaMasters. No fallback sections were used.

A — Metabolic Surgery Research

Acin Gandara, Pereira Perez, Arroyo Martin, Medina Garcia, Mans Muntwyler | Surgery for Obesity and Related Diseases, 2026 | DOI source

Acin Gandara and colleagues report a three-center Spanish randomized trial comparing two Roux-en-Y gastric bypass limb configurations with the same total bypass length. The study randomized 98 patients to either a 150 cm biliopancreatic limb with a 70 cm alimentary limb or the reverse arrangement. At two years, the longer biliopancreatic limb group had greater excess weight loss and total weight loss, with reported values of 89% versus 78% EWL and 39% versus 33% TWL. Complete type 2 diabetes remission was higher at 12 months, 90% versus 64%, but that difference was no longer statistically significant at 24 months.

For bariatric surgeons, the trial keeps limb length in the practical zone rather than treating RYGB as a single uniform operation. The signal favors more weight loss without an observed increase in complications or nutritional deficiencies, but the trial was powered for weight outcomes, not remission durability or uncommon adverse events. Programs considering longer biliopancreatic limbs still need disciplined follow-up, micronutrient surveillance, and patient selection.

Wang, Enagala, Dhalla, Hsu, Samreen, McTaggart | Surgery for Obesity and Related Diseases, 2026 | DOI source

Wang and colleagues used TriNetX data to study Roux-en-Y gastric bypass patients treated between 2015 and 2025. In the propensity-matched analysis, documented nicotine exposure was associated with higher one-year readmission risk and higher marginal ulcer risk. An EHR-coded proxy for non-tobacco nicotine exposure produced a similar pattern, with readmission and marginal ulcer risk ratios close to the tobacco-coded group. A direct comparison did not detect a meaningful difference between tobacco and non-tobacco nicotine exposure.

This is a timely surgical counseling paper because patients increasingly separate vaping, pouches, and other nicotine products from smoking in their own minds. The available data suggest that the relevant exposure may be nicotine itself, not only combustion. Surgeons should be explicit that non-tobacco nicotine is not a benign workaround after bypass, while also acknowledging that EHR diagnosis codes are an imperfect exposure measure.

Dass, Rohde, Wang, Chao, Sweigert | Surgery, 2026 | DOI source

Dass and colleagues interviewed 14 patients at a tertiary center to understand why people pursued metabolic and bariatric surgery despite prior or current GLP-1 receptor agonist use. The qualitative design identified six recurring themes: desire for a durable option, comorbidity improvement, downsides of prior medical therapy, insurance and access barriers, social influence, and a sense that medical and surgical pathways were poorly connected. The sample was small by quantitative standards, but the authors framed the work around thematic saturation and information power. Recruitment during preoperative visits means the findings reflect patients already leaning toward surgery.

The paper gives surgeons language for a conversation that is now routine in clinic. Many patients are not choosing surgery because medication failed in a simple way; they are balancing durability, cost, tolerance, coverage instability, and the need for more structured support. That should push programs to build integrated pathways rather than treating prior GLP-1 use as a detour or a prerequisite. It also reminds teams to ask what the patient learned from medication, not just whether the patient took it.

Nageeb, Ismail, Mohamed, Yacoub, Torfa et al. | Obesity Surgery, 2026 | DOI source

Nageeb and colleagues conducted a randomized open-label trial in 288 high-risk patients undergoing one-anastomosis gastric bypass. Patients were assigned to 15 days of enoxaparin, 30 days of enoxaparin, or 30 days of rivaroxaban after surgery. Across all three arms, the investigators observed only one venous thromboembolism event within 30 days. That very low event count makes the study reassuring in one sense, but it also limits any firm comparison of efficacy or bleeding safety between regimens.

For bariatric surgeons, the study is most useful as a reminder of how hard it is to generate definitive evidence for uncommon but consequential events. Extended prophylaxis decisions still depend on baseline VTE risk, bleeding risk, renal function, adherence, cost, and local pathways. Oral prophylaxis is attractive for patient convenience, but a low-event trial cannot carry a broad practice change by itself. Programs should use this evidence to refine risk-stratified protocols rather than flattening every high-risk patient into one regimen.

B — Science of Obesity Metabolism

Maslin, Shawe, Blowers, Ceulemans, Hart et al. | Obesity Reviews, 2026 | DOI source

Maslin and colleagues combined a systematic scoping review with expert consensus to address incretin-based medications across reproductive health. The group found evidence for 18 of 32 clinical questions, while major gaps remained around contraception, lactation, pregnancy planning, and long-term offspring outcomes. Available data did not show a congenital-anomaly signal, but the evidence base remains incomplete. The consensus therefore reads less like a green light and more like a map of where clinicians must be careful.

Bariatric surgeons increasingly care about this because reproductive counseling now often includes surgery, GLP-1 or GIP therapy, and sometimes both across the same patient journey. Patients need clear advice on medication discontinuation before conception, nutritional optimization, contraception, fertility changes after weight loss, and who owns follow-up when care crosses specialties. The paper supports a coordinated model involving bariatric teams, obesity medicine, obstetrics, primary care, and pharmacy. It also argues against casual reassurance when the data are still thin.

Gasoyan, Schulte, Boyer, Casacchia, Butsch, Le, Aminian, Griebeler | Diabetes, Obesity and Metabolism, 2026 | DOI source

Gasoyan and colleagues studied adults in a large Ohio and Florida health system who discontinued injectable semaglutide or tirzepatide after three to 12 months of treatment. The retrospective EHR cohort focused on what happened in routine care after stopping therapy: which treatments patients received next and how weight changed afterward. The study describes substantial variability rather than one uniform rebound pattern.

The clinical message is that discontinuation is not a single event. Some patients will stop because of cost, supply, side effects, pregnancy planning, insurance changes, or treatment fatigue, and each reason implies a different follow-up plan. Bariatric surgeons should ask about medication interruption and not assume that every patient has the same risk of regain or the same preference for next steps. The study also supports better handoffs between medical weight management and surgery when medication access becomes unstable.

U.S. Department of Veterans Affairs | VA Orlando Health Care, 2026 | VA announcement

The U.S. Department of Veterans Affairs announced an 18-site randomized trial testing weekly semaglutide against placebo for alcohol use disorder. The study plans to enroll more than 600 Veterans aged 18 to 80 with moderate or severe alcohol use disorder. Participants will receive treatment over 24 weeks, followed by safety follow-up, with outcomes that include drinking behavior, health, and quality of life. The announcement is a government trial launch, not a report of efficacy results.

The bariatric relevance is strong even though the indication is not obesity treatment. Alcohol risk after metabolic surgery is a real counseling issue, and GLP-1 biology may intersect with reward pathways in ways that matter for addiction, eating behavior, and postoperative follow-up. Surgeons should not treat semaglutide as an alcohol-use treatment outside evidence-based care, and the VA explicitly warns against self-medicating or replacing proven AUD therapies. Still, the trial is worth watching because it may clarify how incretin drugs affect behaviors beyond appetite.

Xia, Saluja, Muscat, Phongsavan, McBride et al. | Obesity Reviews, 2026 | DOI source

Xia and colleagues reviewed 17 studies examining health literacy in people with severe obesity. The review reports a wide range of low health literacy, from 3.7% to 57.9%, depending on cohort and measurement approach. Low literacy was linked with weight-loss outcomes, appointment attendance, access to information, and perceived provider support.

For bariatric surgeons, health literacy is not a soft add-on. It affects consent, preoperative preparation, nutrition instructions, medication transitions, complication recognition, follow-up attendance, and long-term self-management. Programs should look at whether their materials, videos, portals, and required classes are written for the patients who actually use them. The review also reinforces that literacy-sensitive care is an access intervention, especially for patients already navigating stigma, transportation limits, insurance barriers, and complex multidisciplinary pathways.

C — Metabolic Innovation and Technology

American Medical Association / Digital Medicine Society | American Medical Association, 2026 | Source ↗

The American Medical Association and Digital Medicine Society published a framework describing physician responsibilities as digital health and AI move further into care delivery. The framework centers on preserving trust through human connection, applying clinical judgment, leading new care models, stewarding responsible technology use, and preparing future physicians. It is paired with a roadmap that asks patients, clinicians, developers, payers, policymakers, and health systems to share responsibility for implementation. The document is guidance, not a device evaluation or clinical trial.

Bariatric surgery is exactly the kind of longitudinal, multidisciplinary field where these principles matter. AI tools may help with education, triage, follow-up, documentation, remote monitoring, and risk identification, but the surgeon remains responsible for judgment, escalation, consent, and the human relationship. Programs should read the framework as a governance prompt before adding tools into the patient pathway. The practical question is not whether AI can be installed, but whether it improves care under accountable clinical oversight.

Sean Whooley | MassDevice, 2026 | Source ↗

MassDevice reports that Levita Magnetics received expanded FDA 510(k) clearance for its MARS magnetic-assisted robotic surgery system in bariatric and hiatal hernia repair. The clearance covers use of the Magnetic Surgical System with MARS and includes the company's new 12.5 mm magnetic grasper. The report describes dynamic magnetic positioning for liver retraction and improved access, particularly in patients with high BMI or difficult liver exposure. This is regulatory and device-industry reporting, not independent outcomes evidence.

For surgeons, the relevant question is whether magnetic assistance improves exposure, ergonomics, incision strategy, operative flow, and safety in real bariatric cases. Clearance allows use, but adoption still requires case selection, training, cost analysis, and data collection. Hiatal hernia repair during bariatric surgery is a practical use case because exposure and retraction often determine the quality of the operation. Programs evaluating MARS should track outcomes rather than relying on device claims alone.

Parekh, Sarker | Frontiers in Pharmacology, 2026 | DOI source

Parekh and Sarker review RNA-based approaches being explored for obesity diagnosis and treatment. The article surveys messenger RNA, microRNA, long noncoding RNA, circular RNA, and RNA interference concepts across metabolic regulation, adipose biology, inflammation, and cardiometabolic risk. It also discusses RNA biomarkers as potential tools for risk stratification and therapeutic response. As a mini review, it summarizes a developing field rather than reporting a new clinical trial.

The surgical relevance is early but real. Obesity care is moving toward phenotyping, combination therapy, and mechanisms that may help explain different responses to medications and operations. RNA-based diagnostics could eventually refine risk prediction or identify treatment responders, while RNA therapeutics face delivery, durability, safety, and off-target challenges. Bariatric surgeons do not need to adopt any of this now, but they should recognize the direction of travel: metabolic treatment is becoming more molecular and more individualized.

Abulibdeh, Cajas Ordonez, Celi, Gorijavolu, Izath, Markussen Lunde | PLOS Digital Health, 2026 | DOI source

Abulibdeh and colleagues reviewed 1,357 FDA-cleared AI medical devices through December 2025 and linked them to ClinicalTrials.gov and PubMed evidence. Only 34 devices were associated with registered clinical trials, 12 had publicly available trial results, and 12 had peer-reviewed publications. Just three were evaluated on patient-centered outcomes such as mortality, morbidity, readmission, function, symptoms, or quality of life. The paper is open access under CC BY 4.0 and directly addresses the gap between regulatory clearance and clinical validation.

This should matter to bariatric surgeons before AI tools enter clinics, ORs, call centers, and follow-up pathways. FDA clearance does not necessarily mean that a tool improves outcomes, reduces disparities, or performs well in patients with severe obesity. Programs should ask vendors for prospective data, subgroup performance, workflow effects, and escalation safeguards. The paper gives clinical leaders a straightforward standard: accuracy metrics are not enough if patients never benefit.

D — Metabolic Marketplace

Amylyx Pharmaceuticals | Company release / Reuters coverage, 2026 | Company release

Amylyx reported positive topline results from LUCIDITY, a multicenter randomized, double-blind, placebo-controlled Phase 3 trial of avexitide for post-bariatric hypoglycemia after Roux-en-Y gastric bypass. The trial enrolled 78 adults and randomized participants 3:2 to avexitide 90 mg subcutaneously once daily or placebo. The company reported a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared with placebo, with p=0.000003. Amylyx also reported that all secondary endpoints were met, no treatment-related serious adverse events were seen, and weight did not change.

This is one of the most directly relevant marketplace stories for bariatric surgeons because PBH remains difficult, disruptive, and under-served. A GLP-1 receptor antagonist with positive Phase 3 data could give programs a more specific option beyond diet modification, acarbose, diazoxide, somatostatin analogs, and revisional strategies. The readout is still a company topline announcement rather than a peer-reviewed paper, so surgeons should wait for full data on event definitions, baseline severity, durability, adverse events, and patient-reported outcomes. Amylyx says it plans an NDA submission by the end of 2026.

Maggie Fick and Bhanvi Satija | Reuters, 2026 | Source ↗

Reuters analyzes Novo Nordisk's attempt to regain momentum against Eli Lilly in the obesity-drug market. The report focuses on oral Wegovy, a more aggressive U.S. posture, litigation and marketing pressure, and investor scrutiny ahead of earnings. It also frames the race against a U.S. obesity-drug market expected to exceed $100 billion. This is market reporting, not clinical evidence, but it captures the commercial pressure behind medication access and patient demand.

Bariatric programs should follow these moves because market dynamics shape referrals long before they show up as clinical guidelines. Pricing, supply, direct-to-consumer promotion, employer coverage, and payer policy can determine whether patients arrive optimized, frustrated, undertreated, or medication-experienced. A stronger Novo challenge to Lilly may widen options, but it may also intensify consumer expectations around pills and injections. Surgical counseling needs to stay anchored in durability, risk, access, and individualized sequencing.

Richa Naidu | Reuters, 2026 | Source ↗

Reuters reports that Nestle is treating GLP-1 adoption as a product-development opportunity. The company is using AI, nutrition science, and literature review to design offerings for people using weight-loss medications. Reported targets include protein intake, micronutrient gaps, muscle loss, and hunger after medication discontinuation. The article reflects a consumer-health strategy around GLP-1 therapy rather than a clinical trial of any specific product.

The bariatric lesson is familiar: commercial nutrition will move quickly whenever a treatment changes eating patterns. Surgeons already know that protein adequacy, micronutrients, lean mass, and post-treatment hunger cannot be solved by branding alone. Patients using GLP-1 drugs may benefit from structured nutrition support, but products should not replace dietitian care or evidence-based supplementation. Programs can use the trend as a prompt to explain what high-quality nutrition follow-up looks like across medical and surgical obesity care.

Reuters | Reuters, 2026 | Source ↗

Reuters reports that Novo Nordisk raised its 2026 sales and profit outlook after a stronger second quarter, yet investors focused on softer-than-expected sales for the new Wegovy pill. The report notes that U.S.-listed shares fell after the announcement, with attention on whether oral Wegovy can sustain momentum against Lilly. Reuters also points to investor concern around CagriSema data and broader pipeline pressure. This article overlaps with the prior Novo market story, but it adds the earnings and product-performance angle.

For clinicians, the investor reaction is not the point by itself. The more practical issue is whether oral obesity medications change patient expectations, adherence, coverage patterns, and the timing of surgical referral. Oral therapy may lower the psychological barrier to starting medication, but it does not erase questions about durability, side effects, cost, or inadequate response. Bariatric surgeons should be ready for patients who see an oral GLP-1 as easier than surgery while still needing a realistic comparison of outcomes and follow-up demands.

Production Editor: John D. Scott, MD, FACS | [email protected]

We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected].

The MBS Digest | August 25, 2026 | Vol. 2, Issue 7 | For Educational Purposes Only